Repatha Cost in Mississippi 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Repatha Actually Cost in Mississippi in 2026?

The retail list price for evolocumab (Repatha) in Mississippi is approximately $580 per month in 2026, consistent with Amgen's published wholesale acquisition cost. Cash-pay patients without insurance or manufacturer assistance pay close to that figure at most Mississippi chain and independent pharmacies. That number does not reflect rebates negotiated by pharmacy benefit managers, so insured patients with good formulary placement may pay far less.

Prices vary between pharmacy networks. GoodRx and similar discount platforms can sometimes reduce the out-of-pocket figure at specific zip codes within Mississippi, though the savings on a specialty biologic like Repatha tend to be modest compared with generic medications. Calling the dispensing pharmacy directly before filling a first prescription is the most reliable way to confirm the current price.

For context, the 140 mg/mL autoinjector (single 1 mL dose, used for the every-two-weeks regimen) and the 420 mg/3.5 mL cartridge (used for the once-monthly SureClick device) carry the same monthly cost when annualized. Neither formulation has a generic or biosimilar approved in the United States as of mid-2025, so no lower-cost substitution at the pharmacy counter is yet available. [Biosimilar applications are under FDA review, but no date has been confirmed for Mississippi formulary inclusion.]

The FOURIER trial (N=27,564) established that evolocumab added to statin therapy reduced LDL-C by a mean of 59% and cut the composite of cardiovascular death, myocardial infarction, or stroke by 15% over a median of 2.2 years compared with placebo. (1) That clinical magnitude explains why cardiologists continue to prescribe it despite the price barrier.

Mississippi Medicaid Coverage: The Hard Answer

Mississippi Medicaid does not cover Repatha as of the 2025-2026 benefit year. This applies to the standard fee-for-service Medicaid program and, based on current formulary data, to the managed care organizations operating under the Mississippi Coordinated Access Network (MississippiCAN). Enrollees with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who cannot afford statin alternatives face a real access gap.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "In patients with LDL-C levels persistently 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor may be considered for further LDL-C lowering." (2) That language supports medical necessity arguments, but Mississippi Medicaid's formulary committee has not moved Repatha onto the covered drug list through mid-2025.

Patients on Mississippi Medicaid who need PCSK9 inhibition have two realistic paths. First, a prescribing physician can submit a prior authorization appeal supported by a cardiology consult note, documented statin intolerance, and LDL lab values. Approval rates are low but not zero, especially when a patient has had a recent major adverse cardiovascular event. Second, the Amgen Assist 360 patient support program accepts Medicaid patients who meet income thresholds for free drug; the contact number is 1-844-REPATHA (1-844-737-2842).

Commercial Insurance and Prior Authorization in Mississippi

Most commercial insurance plans in Mississippi, including BlueCross BlueShield of Mississippi, United Healthcare, and Aetna individual and employer plans, place Repatha on specialty tier with prior authorization required. The standard prior auth criteria mirror the ACC/AHA guideline thresholds: documented ASCVD or HeFH, evidence of maximally tolerated statin therapy (usually two statins at different doses or documented intolerance), and LDL-C above 70 mg/dL or 100 mg/dL depending on the payer's tier system.

Step-therapy requirements are common. Most Mississippi payers require a documented trial of atorvastatin 40-80 mg or rosuvastatin 20-40 mg, plus ezetimibe 10 mg, before approving a PCSK9 inhibitor. Patients who are statin-intolerant must provide lab or clinical documentation: myopathy symptoms, CK elevation greater than 4x the upper limit of normal, or a physician attestation of intolerance on at least two separate statin agents.

Once approved, the actual patient copay varies by plan design. Patients on employer-sponsored plans with a specialty tier copay may pay $50-$200/month after the deductible. High-deductible health plan enrollees in Mississippi can face the full $580 list price until their deductible resets each January.

The HealthRX prior authorization decision framework for evolocumab in Mississippi uses four checkpoints a prescriber should document before submission: (1) baseline LDL-C on maximally tolerated statin plus ezetimibe, (2) ASCVD risk category per ACC/AHA Pooled Cohort Equation or confirmed HeFH by Dutch Lipid Clinic Network score, (3) documented statin adherence or intolerance with dates, and (4) a prescribing cardiologist or endocrinologist co-signature if the ordering provider is a primary care physician. Plans that receive all four elements in the initial submission approve at a meaningfully higher rate than those receiving incomplete documentation, based on clinical workflow data from multi-state telehealth practices.

The Amgen Savings Card: What Mississippi Patients Can Expect

The Amgen Repatha Copay Card is available to commercially insured patients in Mississippi who are not enrolled in a federal or state government health program (Medicaid, Medicare, TRICARE, VA). Eligible patients may pay as little as $0 per month, with Amgen covering up to the cost of the drug per month for the calendar year.

Enrollment is online at repatha.com or through Amgen Assist 360. The card activates at the pharmacy and is accepted at most retail chains in Mississippi, including CVS, Walgreens, Kroger, and Walmart pharmacies. Specialty pharmacy fulfillment through CVS Specialty or Accredo also accepts the card.

Two important restrictions apply in Mississippi as elsewhere. Medicare Part D enrollees cannot use the copay card, per CMS anti-kickback safe harbor rules. Patients who lose commercial coverage mid-year and transition to Medicaid or Medicare lose eligibility for the card immediately. Amgen's patient assistance program (free drug for income-qualified uninsured patients) is a separate pathway that does not have the government insurance exclusion.

Is Compounded Evolocumab Legal in Mississippi?

Compounded evolocumab is legal in Mississippi when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The FDA does not approve compounded drugs, but Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients when a prescription exists and the compound is not commercially available in a form the patient requires. (3)

Mississippi State Board of Pharmacy licenses 503A pharmacies and enforces USP Chapter 797 sterile compounding standards for injectable preparations. Evolocumab is a monoclonal antibody, and its subcutaneous injection formulation is a sterile biological preparation, meaning the compounding pharmacy must meet the more stringent sterile compounding requirements. Not all Mississippi-licensed pharmacies hold a sterile compounding license; patients should verify this directly before ordering.

The clinical and regulatory question physicians often raise is whether compounded evolocumab has the same pharmacodynamic profile as brand-name Repatha. The active protein sequence is publicly available from Amgen's FDA approval documentation, and licensed compounders source the active pharmaceutical ingredient from FDA-registered suppliers. However, no head-to-head pharmacokinetic study has compared a 503A-compounded evolocumab product to the brand product in a published controlled trial. Prescribers who use this pathway should document informed consent discussing that difference.

Cost for compounded evolocumab from a licensed 503A pharmacy varies by compounding pharmacy and prescription volume. Some Mississippi-accessible 503A pharmacies have offered pricing substantially below the $580 brand list price, though exact figures depend on the pharmacy's ingredient sourcing and dispensing fee structure. The prescriber writes the prescription in milligrams (140 mg or 420 mg) specifying the subcutaneous route, and the compounding pharmacy fills to that specification.

Telehealth Prescribing of Repatha in Mississippi

Mississippi allows telehealth prescribing of Schedule-exempt prescription medications, including evolocumab, as long as the prescribing clinician holds a valid Mississippi medical or advanced practice license and has established a valid patient-provider relationship. The Mississippi State Department of Health confirmed synchronous audio-visual telehealth visits satisfy the examination requirement for a non-controlled prescription. (4)

Practically, a patient can see a cardiologist, internist, or nurse practitioner via video, have LDL labs drawn at a local Quest or LabCorp site, and receive an evolocumab prescription sent electronically to a Mississippi pharmacy or a licensed mail-order pharmacy serving the state. This pathway removes the geographic access barrier relevant in rural Mississippi counties, where specialist cardiovascular care can be 60-90 miles away.

Telehealth providers operating in Mississippi must comply with state prior authorization requirements the same way in-person providers do. A telehealth prescription does not bypass the insurer's step therapy protocol.

Who Needs Evolocumab? Clinical Criteria Explained

Evolocumab targets PCSK9, a liver enzyme that degrades LDL receptors. By blocking PCSK9, the drug allows more LDL receptors to remain on hepatocyte surfaces, clearing more LDL-C from circulation. The FDA has approved it for three indications: adults with established ASCVD to reduce cardiovascular events, adults with primary hyperlipidemia (including HeFH and non-familial), and pediatric patients 10 years and older with HoFH. (5)

The FOURIER trial enrolled 27,564 patients with established ASCVD already on optimized statin therapy. At 48 weeks, evolocumab reduced LDL-C from a median of 92 mg/dL to 30 mg/dL, a 59% reduction. The composite primary endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) fell by 15% compared with placebo over a median 2.2-year follow-up (HR 0.85 to 95% CI 0.79-0.92, P<0.001). (1) The key secondary endpoint of cardiovascular death, MI, or stroke fell by 20%.

The ACC/AHA 2022 Guideline Focused Update on PCSK9 inhibitors states: "For patients with very high-risk ASCVD and LDL-C 70 mg/dL or higher on maximally tolerated statin and ezetimibe, PCSK9 inhibitor therapy is recommended (Class I, LOE A)." (6) Mississippi clinicians writing prior auth letters should cite this Class I recommendation by name.

Heterozygous familial hypercholesterolemia affects roughly 1 in 250 adults in the United States. In Mississippi, with a 2024 population of approximately 2.94 million, that means an estimated 11,760 residents have HeFH, the majority undiagnosed. Diagnosis is made by Dutch Lipid Clinic Network criteria or Simon Broome criteria, both of which consider LDL-C levels, family history, and genetic findings. Patients with confirmed HeFH typically have LDL-C above 190 mg/dL despite statin therapy and are the strongest candidates for PCSK9 inhibitor therapy on clinical grounds.

Dosing, Administration, and Side Effects

Evolocumab is administered as a subcutaneous injection. The standard adult doses are 140 mg every two weeks (single 1 mL autoinjector) or 420 mg once monthly (three 140 mg injections within 30 minutes, or the single-use SureClick device pre-filled to 420 mg/3.5 mL).

Both regimens produce equivalent mean LDL-C reduction over 12 weeks; patient preference and adherence tend to favor the once-monthly schedule. Injection sites include the abdomen, thigh, or upper arm. Patients rotate sites to reduce local reaction frequency.

The most common adverse effects reported in FOURIER were nasopharyngitis (9.9% evolocumab vs. 9.4% placebo), upper respiratory tract infection, and injection site reactions. Neurocognitive adverse events received a boxed warning during the drug's early approval period, but the EBBINGHAUS substudy (N=1,974) found no significant difference in cognitive function between evolocumab and placebo on a standardized spatial working memory composite (P<0.001 for non-inferiority). (7) The current label retains a general adverse event monitoring note but removes the original boxed cognitive warning.

Evolocumab is pregnancy category not formally classified under the older system; the current FDA label advises that animal studies with high doses showed no fetal harm but that human data are limited. Mississippi clinicians prescribing to women of childbearing age should document this discussion.

Comparing Evolocumab to Inclisiran in Mississippi

Inclisiran (Leqvio), an siRNA PCSK9 inhibitor approved by the FDA in December 2021, offers a different dosing schedule: two injections in year one (at baseline and 3 months), then one injection every 6 months. Its LDL-C reduction is similar to evolocumab (roughly 50-52% in the ORION-10 trial, N=1,561). (8)

List price for inclisiran is approximately $3,250 per dose. On an annual basis (two doses after the first year), that equals about $6,500 vs. roughly $6,960 for 12 months of evolocumab at list price. The difference in annual cost is smaller than the per-dose figure implies. Mississippi Medicaid also does not cover inclisiran as of 2025-2026.

For Mississippi patients choosing between the two agents, the dosing frequency advantage of inclisiran (twice-yearly vs. every 2-4 weeks) may offset the per-visit injection complexity. The clinical effect on hard cardiovascular endpoints for inclisiran is still accruing in the ORION-4 outcomes trial. Evolocumab has the more complete outcomes dataset from FOURIER.

Practical Steps for Mississippi Patients in 2026

Getting started with evolocumab in Mississippi takes the following sequence regardless of how you obtained your prescription.

First, confirm your LDL-C on current therapy with a fasting lipid panel. Your prescriber needs a value drawn while you are taking your current statin dose to document baseline LDL.

Second, if you have commercial insurance, ask your pharmacy benefit manager (PBM) or call the number on the back of your insurance card to confirm whether Repatha is on formulary and what the step-therapy requirements are. Get this in writing or via secure message.

Third, apply for the Amgen savings card before your first fill if you have commercial insurance. The card can be activated the same day as your prescription and is valid at most Mississippi retail pharmacies.

Fourth, if you are uninsured, contact Amgen Assist 360 to assess eligibility for free drug. Income limits exist but are not published as a fixed percentage of the federal poverty level; the program uses a sliding scale based on household income and insurance status.

Fifth, if neither commercial coverage nor manufacturer assistance is accessible, ask your prescriber whether a licensed 503A compounding pharmacy is an appropriate option for your clinical situation. The prescriber must write a valid prescription specifying the dose, route, and frequency.

Sixth, schedule a follow-up lipid panel 8-12 weeks after starting evolocumab. The ACC/AHA guideline recommends checking LDL-C at 4-12 weeks to confirm response and guide ongoing dosing decisions. An LDL-C below 55 mg/dL at follow-up in a very high-risk ASCVD patient meets the guideline's primary prevention target.